- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
More ▼
Key statistics
On Wednesday, Inhibikase Therapeutics Inc (IKT:NAQ) closed at 1.15, 45.63% above the 52 week low of 0.79 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.15 |
---|---|
High | 1.26 |
Low | 1.15 |
Bid | 1.12 |
Offer | 1.24 |
Previous close | 1.21 |
Average volume | 30.91k |
---|---|
Shares outstanding | 7.22m |
Free float | 6.32m |
P/E (TTM) | -- |
Market cap | 8.30m USD |
EPS (TTM) | -3.38 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:59 BST.
More ▼